Motesanib, an oral VEGF, a growth factor and platelet-derived receptor kit with or without panitumumab in patients with refractory Examines rer disease. A number of mutant BRAF kinase inhibitors in clinical development, as discussed above. AMG 102 is a monoclonal antique Bodies examined against experimental human hepatocyte growth factor in combination with panitumumab in patients with metastatic colorectal cancer. XL880 Foretinib GSK1363089 5th Neoadjuvant and adjuvant therapy, because the clinical benefit of antiEGFR monoclonal antique Body in patients with metastatic disease, the evaluation of these therapies . In the adjuvant setting, the elimination of micrometastatic disease with h Heren cure rates associated. N0147 randomized 1760 patients with resected stage III colon cancer KRAS WT FOLFOX with or without cetuximab.
The vorl INDICATIVE analysis of premature closing out Ung of the study after it was found that no group of patients received cetuximab. Included at the beginning of this study, patients independently Ngig of KRAS mutational status, and among the 658 patients with mutant KRAS, led survive the addition of cetuximab to FOLFOX in the disease-free and free Change trend lack OS. Patients with rectal cancer is a logical target EGFR in combination with neoadjuvant radiotherapy. Retrospective analyzes have lower completely pathological’s Full response rate and shorter DFS in patients with rectal cancer were treated with EGFR expression neoadjuvant RT, showed, suggesting that the radiation sensitivity of targeting EGFR erh Can ht.
Several phase I / II trial of cetuximab and combination neoadjuvant chemoradiotherapy in patients with rectal cancer. These studies have shown that cetuximab combined with the pr Operative chemoradiation can k, But CRP levels were low. Two of these studies were subsequent analyzes that correlate to the mutational status of the KRAS gene with a response rate. Among patients with KRAS WT tumors, Bengala et al. reported a trend towards a h Heren rate of tumor regression, but reached statistical significance. Debucquoy et al. found no correlation between KRAS WT tumors and pathologic response to therapy. To our knowledge, panitumumab has not been studied in combination with RT in patients with rectal cancer. Given the failure of monoclonal Rpern antiEGFR benefit in adjuvant therapy for stage III WT KRAS cancer c Lon, to demonstrate the value of further study of these agents for cancer of the rectum, is questionable.
Gefitinib has shown pr Improved clinical radiosensitizing. Valentini et al. investigated the association of gefitinib, a continuous infusion of 5-fluorouracil and pelvic RT in 41 patients with locally advanced rectal cancer and reported a CRP of 30%, but toxicity was an issue and further studies are needed to determine security association this.